Tag Archives for Pharmacological Misuse-Abuse

Minnesota Announces New Strategies Dealing with Opioid Abuse

Minnesota has been a pioneer of sorts in the manner in which it approaches policies of addressing prescription opioid abuse. One goal is to train physicians in the basics of addiction, opiate prescribing and alternative approaches to pain management, according … Continue reading

15. September 2012 by Michael Douglas, MD, MBA
Categories: Knowledge & Medicine, Pharma & Devices, Politics & The Law, Science & Research | Tags: , , , , , , , , | Comments Off

Massive Medicaid Fraud Bust Exposes New Challenges

It constantly amazes just how creative Medicaid fraud can be. The massive New York state bust involved 48 people and cost taxpayers over half a billion bucks. It was an elaborate scheme that preyed on poor Medicaid beneficiaries to sell … Continue reading

18. July 2012 by Michael Douglas, MD, MBA
Categories: CMS, Pharma & Devices, Politics & The Law | Tags: , | Comments Off

Functionally Strangled by Drug Treatment, Minnesota Patient Loses Trust but Gains Empowerment

When she was diagnosed with multiple sclerosis, a Minnesota woman thought that her carefully chosen neurologist had her best interests in mind when prescribing initial treatments to modify the disease. That was before a little detective work uncovered the real … Continue reading

09. December 2011 by Michael Douglas, MD, MBA
Categories: Corporate, Diversions | Tags: , , , , , , , , , , | Comments Off

Study: Paucity of Drugs Responsible for Nearly 100K Acute Hospitalizations in Elderly

This item comes as no surprise to those of us who primarily treat the elderly. According to researchers, nearly 100,000 hospitalizations every year are linked to adverse drug events such as allergic reactions and unintentional overdoses. Nearly half, or 48.1 … Continue reading

26. November 2011 by Michael Douglas, MD, MBA
Categories: Pharma & Devices | Tags: , , , , , , , , , , , , , | Comments Off

Pharma Company to Pay Over $900M from Vioxx Marketing Practices

The DOJ decision has been handed down. Merck Co. will pay $321.6 million in criminal fines and $628.4 million as a civil settlement agreement. It also will plead guilty to a misdemeanor charge stemming from the premature marketing of the … Continue reading

22. November 2011 by Michael Douglas, MD, MBA
Categories: Corporate, Pharma & Devices, Politics & The Law | Tags: , , , , | Comments Off

Obama to Sign Executive Order Addressing Shortages of Medicines

The president will issue an executive order today requiring the FDA to act on potential drug shortages in the phrama marketplace. Previously, drug companies were only required to notify the agency if a preparation was to be discontinued. Any other … Continue reading

31. October 2011 by Michael Douglas, MD, MBA
Categories: Corporate, Pharma & Devices | Tags: , , , , , | Comments Off

FDA Criticized for Lack of Controls over Increasing Prescription Narcotic Abuse

The rise in prescription drug abuse in this country has been muted somewhat by the traditional messaging by anti-drug campaigns which advocate the overarching “just say no” philosophy … and have done so since the heady days of the Reagan … Continue reading

21. August 2011 by Michael Douglas, MD, MBA
Categories: Corporate, Healthcare Policy & The Media, Pharma & Devices, Science & Research | Tags: , , , , , , , , , | Comments Off

SCOTUS Rules on a Couple of Important Pharma Cases

Clarence Thomas wrote for the 5-4 decision in which companies were shielded from lawsuits by consumers suffering from adverse effects of certain drugs. Anthony Kennedy, the SCOTUS justice often seen as the court’s swing vote, wrote for the majority opinion … Continue reading

26. June 2011 by Michael Douglas, MD, MBA
Categories: Knowledge & Medicine, Pharma & Devices, Politics & The Law | Tags: , , , , , , , , | Comments Off

France: Avandia Congener May Have Troublesome, Adverse Risk

Somewhat interesting that the TZD class of antidiabetic drugs in this country has been known mostly for a good (pioglitazone) and bad (rosiglitazone) actor — as the drugs work very similarly in treating the disorder. The latter drug has essentially … Continue reading

12. June 2011 by Michael Douglas, MD, MBA
Categories: Pharma & Devices, Science & Research | Tags: , , , , | Comments Off

Medication Shortages Another Area of Concern for Hospitals

Drug shortages in hospitals were somewhat of a rarity at one time. For many reasons (not all of them economic) a trend in the late 2000s continuing up to today notes a disturbing pattern of many pharmaceuticals whose usage permeates … Continue reading

31. May 2011 by Michael Douglas, MD, MBA
Categories: Pharma & Devices, Science & Research | Tags: , , , , , , , , , , , , , | Comments Off

Bill to Modernize Medicare Payment Information to Providers Nets Unified Support

It’s got bipartisan support, and it would call for transparency the amount that Medicare pays providers for treating patients.[1] Sens. Wyden (D-MA) and Grassley (R-IA) are introducing the Medicare Data Access for Transparency and Accountability Act [link, here]. Its passage … Continue reading

11. April 2011 by Michael Douglas, MD, MBA
Categories: CMS, Politics & The Law | Tags: , , , , , , , , , | Comments Off

Report: Minnesota’s Pharma Disclosure Laws Fail to Provide Audit Mechanism

Policy wonks, regulatory agencies, legislators, and just about any interested person can usually obtain access to a physician’s relationship with pharma companies and the drugs they pitch. It wasn’t too long ago that this information was more challenging to find, … Continue reading

14. December 2010 by Michael Douglas, MD, MBA
Categories: Corporate, Healthcare Policy & The Media, Knowledge & Medicine, Pharma & Devices, Politics & The Law, Science & Research | Tags: , , , , , , , | Comments Off

Analysis: Pharma Payouts to Docs Increasingly Irresponsible in the Age of Reform

The role of the physician as spokesperson in the name of “expert analysis” is finally being called for what it is — a sham. Over the middle to latter years of my training, I cannot count the number of ┬átimes … Continue reading

19. October 2010 by Michael Douglas, MD, MBA
Categories: Corporate, Healthcare Policy & The Media, Knowledge & Medicine, Science & Research | Tags: , , , , , , , , , | Comments Off

← Older posts